Trials / Recruiting
RecruitingNCT06034977
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
Genotype Selected, Randomized, Open Label, Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Chang Gung Memorial Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the clinical outcomes of Lenvatinib treatment alone or Lenvatinib + ADI-PEG20 combination treatment in advanced HCC patients with BCLC stage C.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADI-PEG20 | Lenvatinib + ADI-PEG20 combination treatment. |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2026-07-23
- Completion
- 2026-07-23
- First posted
- 2023-09-13
- Last updated
- 2023-09-13
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT06034977. Inclusion in this directory is not an endorsement.